Invesco’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-109,137
Closed -$7.87M 3812
2025
Q4
$7.87M Sell
109,137
-79,226
-42% -$5.12M ﹤0.01% 2009
2025
Q3
$8.21M Sell
188,363
-54,700
-23% -$2.21M ﹤0.01% 1948
2025
Q2
$6.9M Sell
243,063
-45,076
-16% -$1.34M ﹤0.01% 2012
2025
Q1
$8.51M Buy
288,139
+193,376
+204% +$6.02M ﹤0.01% 1872
2024
Q4
$2.76M Sell
94,763
-215,593
-69% -$9.01M ﹤0.01% 2498
2024
Q3
$14.3M Sell
310,356
-39,999
-11% -$1.74M ﹤0.01% 1650
2024
Q2
$14.3M Sell
350,355
-22,961
-6% -$659K ﹤0.01% 1602
2024
Q1
$9.53M Buy
373,316
+245,444
+192% +$3.85M ﹤0.01% 1843
2023
Q4
$1.16M Sell
127,872
-10,128
-7% -$67.7K ﹤0.01% 2829
2023
Q3
$880K Buy
138,000
+44,653
+48% +$385K ﹤0.01% 2927
2023
Q2
$1.04M Sell
93,347
-73,436
-44% -$921K ﹤0.01% 2875
2023
Q1
$2.56M Buy
166,783
+97,862
+142% +$2.15M ﹤0.01% 2539
2022
Q4
$1.53M Sell
68,921
-78,655
-53% -$1.17M ﹤0.01% 2747
2022
Q3
$2.41M Buy
147,576
+112,540
+321% +$2.15M ﹤0.01% 2561
2022
Q2
$509K Buy
35,036
+4,799
+16% +$71.4K ﹤0.01% 3317
2022
Q1
$558K Buy
30,237
+15,442
+104% +$262K ﹤0.01% 3335
2021
Q4
$351K Buy
14,795
+533
+4% +$12.7K ﹤0.01% 3545
2021
Q3
$352K Buy
14,262
+2,966
+26% +$64.5K ﹤0.01% 3587
2021
Q2
$279K Buy
+11,296
New +$263K ﹤0.01% 3658

Other funds holding RNAM

Invesco's RNAM Position: Q1 2026 in Review

Invesco sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 109,137 shares — an estimated $7.87M sold.

Invesco first reported a position in RNAM in Q2 2021 and held it in 19 quarters. The position peaked at $14.3M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Invesco reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Invesco sold 109,137 Avidity Biosciences shares in Q1 2026, an estimated $7.87M.
  • Invesco first reported a position in Avidity Biosciences in Q2 2021 and held it in 19 quarters.
  • Invesco's Avidity Biosciences position peaked at $14.3M in Q2 2024.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.